Affiliations:
1 Department of Dermatology, Xiangya Hospital, Central
South University, Changsha, China, 410008;
2 Allergy subspecialty direction, Hunan Key Laboratory
of Skin Cancer and Psoriasis, Xiangya Hospital, Central South
University, Changsha, China, 410008;
3 National Clinical Research Center for Geriatric
Disorders, Xiangya Hospital, Central South University, Changsha, Hunan,
China, 410008.
Corresponding Authors: Jie Li, Department of Dermatology,
Xiangya Hospital, Central South University, Changsha, Hunan, China. Fax:
+86 073184327332. E-mail: xylijie@csu.edu.cn
† BJ. Zhou and C. Peng contributed equally to this
work; *J. Li and X. Chen contributed equally to this work.
Funding sources: This work was supported by funding from Grant
No.81974476,82173424, 81673065,81830096, 81773341 by the National
Natural Science Foundation of China. This study was also supported by
the Program for Introducing Talents of Discipline to Universities (111
Project, No. B20017)
Conflicts of Interest: None declared.
Ethical approval status: This study was approved by the Ethics
Review Committee of Xiangya Hospital (ethical approval
number:2021030471).
Patient Consent on File: An Informed consent was obtained from
the parent or legal guardian.
Manuscript word count: 586 words
References: 6
Figures and tables: 2
Supplementary figures: 1
Supplementary tables: 3
Attachments: STROBE checklist, research protocol, and statistical
analysis plan
Keywords: atopic dermatitis, children, dupilumab, drug
response, real-world study